22
STARTUP X 1 Mentoring for Startups ReviveMed Unlocking the Value of Metabolomics Leila Pirhaji, Ph.D. Founder and CEO [email protected]

Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

  • Upload
    others

  • View
    0

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

STARTUP X 1

Mentoring for Startups

ReviveMedUnlocking the Value of Metabolomics

Leila Pirhaji, Ph.D.Founder and CEO

[email protected]

Page 2: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

Presentation Overview

• ReviveMed’s Summary

• My Journey

• The role of my mentors in my journey

Page 3: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

New Use of Existing Drugs Could Save Millions of Lives

Non-Alcoholic Fatty Liver has no Treatments

10,000s of Existing Drugs,>$1 Trillion of R&D

Page 4: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

ReviveMed Solves the Puzzle Using Metabolomics

Existing AI/Machine-LearningLast decade

Metabolites>40,000 Small Molecules

ProteinDNA RNA

ReviveMedNow!

Page 5: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

ReviveMed’s Pioneering Machine-Learning Algorithm

Developed at MIT Our patent-pending technology

was published at:

Page 6: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

Because of tremendous diversity of metabolites, current platforms can only detect 500-700 of them (<5%)

Metabolomics had been Underutilized, Until Now!

Page 7: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

ReviveMed Enables Leveraging Metabolomics

Reduces the need for costly and slow processes to identify large-set of metabolites

Proprietary Database Machine-

Learning

Page 8: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

ReviveMed Revolutionizes Discovering New Treatments

Therapeutic Insights

Pre-clinically validatedReviveMed

Tissue Serum

Hospitals/Disease Associations

CROs

Whitehead/Harvard Metabolomic Facilities

I. Disease PathwaysII. Therapeutic TargetsIII. Existing (pre-, post-, no-

patent) drug CandidatesIV. Serum Biomarkers

Saving 100s of Millions and Years from Discovery to Clinic

Page 9: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

ReviveMed Creates Value for Patients and Pharma

$55 B

Market Opportunity

Technology FitUniquely leveraging data

from 1000s of metabolites

The Next Breakout

Biotech Market

Market Size> 60M Americans

>$35B by 2025

ReviveMed Platform

Therapeutics for metabolic diseases

1st Therapeutic Focus

Therapeutics for non-alcoholic fatty liver

Page 10: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

It wouldn’t be possible without Boston's Biotech Ecosystem

Boston’s Biotech

Ecosystem

Mentors

Academic research

Investment capital

Talent

Government

Industry

Page 11: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

Boston is the Hollywood for Biotech Entrepreneurs

Legendary Stars Legendary Startups

Page 12: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

My Entrepreneurial Journey – Academic Phase

Catching the entrepreneurial virus

Learning entrepreneurship

Practicing entrepreneurship

Page 13: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

My Entrepreneurial Journey – Beyond Academia

Page 14: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

Most Important Part of these Programs are Mentorships

Page 15: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

Always Seeking for Mentors

Page 16: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

The Power of Mentorships

Page 17: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

Leveraging Mentors’ Professional Network

Page 18: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

Foster Mentorship

Page 19: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

Moving Beyond Mentor-Mentee Relationships

Page 20: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

ReviveMed’s World-Class Team & Advisors

Prof. Ernest FraenkelCo-founder & Board

Member

Associate Professor of at MIT

Dr. Andrey Zarur

Board Member

CEO at GreenLightBiosciences

Lecturer at MIT Sloan

Prof. Clary ClishScientific Advisor

Director of Metabolomics Broad Institute

Prof. Matthew Vander Heiden

Scientific advisor

Associate Professor of Biology at MIT

Scientific advisor

Director of Data Sciences Fortune 500 Pharma

No public disclosures

Leila Pirhaji, Ph.D.Founder & CEO

Inventor of the technologyPhD in Bioengineering at MIT

Page 21: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

ReviveMed: An Award-Winning Start-Up Company>$50 K in Cash Prize $50 K of Lab Space $200 K in Cloud Computing Credits

Machine-learning CompetitionTop 10 finalists

Analytic PrizeTop 26 Winners of 2017

Page 22: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates

22

www.revive-med.com

617.955.6425

[email protected]

@Revive_Med

ReviveMedTransforming Metabolomics Data into

the Right Therapeutics for the Right Patients